OC
ADMA icon

Oppenheimer & Co’s ADMA Biologics ADMA Stock Holding History

Oppenheimer & Co’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$475K Sell
56,798
-4,272
-7% -$38.9K 0.01% 1276
2026
Q1 		$550K Buy
+61,070
New +$964K 0.01% 1152
2025
Q4 		– Sell
-49,230
Closed -$722K – 1534
2025
Q3 		$722K Buy
49,230
+835
+2% +$14.3K 0.01% 1041
2025
Q2 		$881K Sell
48,395
-6,892
-12% -$141K 0.01% 914
2025
Q1 		$1.1M Buy
55,287
+16,871
+44% +$292K 0.02% 766
2024
Q4 		$659K Sell
38,416
-56,522
-60% -$1.06M 0.01% 968
2024
Q3 		$1.9M Buy
94,938
+43,836
+86% +$682K 0.03% 571
2024
Q2 		$571K Sell
51,102
-43,108
-46% -$362K 0.01% 965
2024
Q1 		$622K Sell
94,210
-27,726
-23% -$152K 0.01% 918
2023
Q4 		$551K Buy
121,936
+4,801
+4% +$17.8K 0.01% 940
2023
Q3 		$419K Sell
117,135
-2,255
-2% -$8.68K 0.01% 1009
2023
Q2 		$441K Sell
119,390
-6,500
-5% -$24.1K 0.01% 1024
2023
Q1 		$417K Buy
125,890
+3,065
+2% +$10.6K 0.01% 1009
2022
Q4 		$477K Sell
122,825
-77,500
-39% -$239K 0.01% 923
2022
Q3 		$487K Buy
200,325
+30,903
+18% +$74.1K 0.01% 907
2022
Q2 		$335K Buy
+169,422
New +$333K 0.01% 1064
2020
Q2 		– Sell
-10,836
Closed -$31K – 1254
2020
Q1 		$31K Buy
10,836
+810
+8% +$2.8K ﹤0.01% 1167
2019
Q4 		$40K Buy
+10,026
New +$43.7K ﹤0.01% 1258

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Oppenheimer & Co's ADMA Position: Q2 2026 in Review

Oppenheimer & Co reduced its ADMA Biologics (ADMA) stake by 7% in Q2 2026, selling an estimated $38.9K and leaving 56,798 shares worth $475K. The position accounts for 0.01% of the portfolio, ranked #1276.

Oppenheimer & Co first reported a position in ADMA in Q4 2019 and has held it in 18 quarters since. The position peaked at $1.9M in Q3 2024. 322 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Oppenheimer & Co held 56,798 shares of ADMA Biologics worth $475K as of Q2 2026.
  • Oppenheimer & Co sold 4,272 ADMA Biologics shares in Q2 2026, an estimated $38.9K.
  • ADMA Biologics made up 0.01% of Oppenheimer & Co's portfolio in Q2 2026, its #1276 holding.
  • Oppenheimer & Co first reported a position in ADMA Biologics in Q4 2019 and has held it in 18 quarters since.
  • Oppenheimer & Co's ADMA Biologics position peaked at $1.9M in Q3 2024.
  • 322 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Oppenheimer & Co's 13F filing for Q2 2026, filed 3 Aug 2026.